Rocket Pharmaceuticals to Present at the Bank of America Securities 2022 Global Healthcare Conference
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is set to present at the Bank of America Securities Healthcare Conference on May 11 at 2:20 p.m. ET. The company specializes in developing genetic therapies for rare childhood disorders, including Fanconi Anemia and Danon Disease. Rocket utilizes a platform-agnostic approach, focusing on tailored therapy solutions. Given the ongoing impact of COVID-19, the company emphasizes the safety and effectiveness of its product candidates, while also addressing potential delays in clinical trials.
- None.
- None.
About
Rocket Cautionary Statement Regarding Forward-Looking Statements
Various statements in this release concerning Rocket’s future expectations, plans and prospects, including without limitation, Rocket’s expectations regarding its guidance for 2022 in light of COVID-19, the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), and Danon Disease, the expected timing and data readouts of Rocket’s ongoing and planned clinical trials, Rocket’s plans for the advancement of its Danon Disease program following the lifting of the FDA’s clinical hold and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket’s ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket’s ongoing trials, our expectations regarding the delays and impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket’s Annual Report on Form 10-K for the year ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005195/en/
Media
Director, Corporate Communications
kgiordano@rocketpharma.com
Investors
Vice President, Investor Relations and Corporate Finance
investors@rocketpharma.com
Source:
FAQ
What is Rocket Pharmaceuticals presenting at the Bank of America Securities Healthcare Conference?
When is Rocket Pharmaceuticals scheduled to present at the conference?
What diseases is Rocket Pharmaceuticals targeting with its therapies?
What is Rocket Pharmaceuticals' approach to developing therapies?